TRW & Co · Trade, Regulation & ESG
Clinical Research Agreements in Singapore
Clinical trials in Singapore need two things to line up: the right regulatory route with HSA or MOH, and contracts that allocate the same duties to the same parties. This guide explains CTA, CTN and HBRA requirements, the local sponsor role, and how to negotiate site, CRO, material transfer and data agreements without delaying activation.
Key pointHSA looks to a locally registered sponsor for every regulated trial; if a CRO or affiliate fills that role, the contract chain must give it the authority, information and indemnity to discharge it, or regulatory and contractual responsibility will diverge.
At a glance
CTA in 30 working days
HSA targets 30 working days for a Clinical Trial Authorisation, 15 for certain Phase 1 studies and 60 for Class 2 CTGTP trials.
CTN in 5 working days
Trials using registered products within their approved labels can proceed on a Clinical Trial Notification, filed only after IRB approval.
Device trials under HBRA
Medical device trials need no HSA trial approval but are governed by the Human Biomedical Research Act and institutional review boards.
Local sponsor required
HSA expects the sponsor to be a locally registered entity; it may delegate to a CRO but keeps overall responsibility.
ICH E6 (R3) in force
HSA implemented ICH E6 (R3) principles and Annex 1 on 1 January 2026, with Annex 2 following on 1 January 2027.
Swipe or scroll →
Clinical trials in Singapore and the agreements behind them
Clinical trials in Singapore run on two tracks at once: a regulatory track, where the Health Sciences Authority (HSA) or the Ministry of Health (MOH) decides whether and how the study may proceed, and a contractual track, where sponsors, contract research organisations (CROs), hospitals and investigators agree who does what, who pays, who owns the results and who carries the risk. The agreements only work if they reflect the regulatory roles exactly.
Singapore's public hospitals, academic medical centres and research institutes host a steady flow of industry-sponsored and investigator-initiated studies, including early-phase work. Sponsors value predictable timelines and a regulator that publishes its targets. Institutions value clear terms on indemnity, publication and intellectual property. Disputes usually arise where the contract and the regulatory reality diverge.
This page explains how the framework allocates responsibility and how clinical research agreements should be built around it: clinical trial agreements with sites, master services agreements with CROs, material transfer and data sharing agreements, and investigator-initiated study support.
The regulatory framework for clinical trials in Singapore
Which regime applies depends on the product. HSA's clinical trials overview sets out the split:
| Study type | Main legislation | Regulatory instrument |
|---|---|---|
| Therapeutic products and Class 2 cell, tissue and gene therapy products (CTGTPs) | Health Products Act; Health Products (Clinical Trials) Regulations 2016 | Clinical Trial Authorisation (CTA) or Clinical Trial Notification (CTN) from HSA |
| Medicinal products, such as Chinese proprietary medicines or health supplements studied for disease | Medicines Act; Medicines (Clinical Trials) Regulations 2016 | Clinical Trial Certificate (CTC) from HSA |
| Medical devices | Health Products Act and Human Biomedical Research Act 2015 | No HSA trial approval; HBRA governance through MOH |
| Class 1 CTGTPs and observational studies | Human Biomedical Research Act 2015 | Institutional review board and MOH framework |
The Health Products (Clinical Trials) Regulations 2016 govern most industry drug trials. The Human Biomedical Research Act 2015 (HBRA) governs human biomedical research more broadly, including device studies, and is administered by MOH. Many studies touch both: a drug trial needs HSA authorisation and institutional ethics review, and any tissue or data retained for future research falls under the HBRA tissue framework.
CTA or CTN?
A CTA is needed for trials of an unregistered therapeutic product or Class 2 CTGTP, or of a registered product used outside its approved label, for example in a new indication, population, route or dosing regimen. Trials in healthy volunteers generally need a CTA. A CTN is enough where only locally registered products are used in line with their approved labels. HSA's target is 30 working days for a CTA, 15 for certain Phase 1 bioequivalence, bioavailability, food-effect and drug interaction studies, and 60 for Class 2 CTGTP trials. A CTN has a 5-working-day target. HSA charges no fees for clinical trial applications.
Timing matters for the contract plan. A CTA may be submitted in parallel with the ethics submission, but a CTN can only be submitted after institutional review board (IRB) approval. Site activation dates in the clinical trial agreement should follow that sequence.
HBRA governance: institutions and IRBs
Under the HBRA, research must be supervised by a research institution, which must appoint at least one IRB to review the study's ethics, the researchers' qualifications and the suitability of the site. The institution must notify MOH at least 30 days before research begins and file an annual declaration of compliance. Appropriate consent must generally be written, given after required information has been explained, and witnessed. Restricted research, such as certain embryo and stem cell work, needs MOH approval as well. MOH's HBR regulation page links the Act, regulations and guidance.
The local sponsor and allocation of responsibility
For HSA-regulated trials, the applicant is the local sponsor: the local company or institution that takes responsibility for initiating, managing or financing the trial. HSA expects the sponsor to be a locally registered business entity. An overseas pharmaceutical company therefore needs its Singapore affiliate, a CRO or another local entity to act as local sponsor, and that choice should be reflected precisely in the agreements.
The sponsor may delegate duties to a CRO or other service provider, but it retains overall responsibility for them. Agreements with investigators and service providers must be documented before activities begin. That rule is the anchor for every contract in the study.
Clinical trial agreement
Between sponsor (or CRO on its behalf), institution and often the principal investigator. It sets the protocol obligations, budget, payment triggers, indemnity, insurance, confidentiality, publication and IP terms.
CRO master services agreement
Defines which sponsor duties the CRO takes on, the transfer of regulatory obligations, service levels, data handling and audit rights. The sponsor's ultimate responsibility to HSA does not move.
Local sponsor arrangement
Where a CRO or affiliate is local sponsor for an overseas company, an agreement must allocate safety reporting, records, regulatory correspondence and the cost of any HSA action.
Material and data agreements
Material transfer and data sharing agreements govern samples sent to overseas laboratories, future research use, tissue banking under the HBRA and cross-border transfers of personal data.
Our guide to clinical research pathways walks through the regulatory side; this section focuses on the contracts.
Key negotiation points in clinical research agreements
Indemnity, insurance and subject injury
Institutions expect the sponsor to indemnify them against claims arising from the investigational product and the protocol, subject to carve-outs for the institution's negligence, deviation from the protocol and breach of law. Sponsors usually need to show clinical trial insurance that responds in Singapore. The agreement should also set out how trial-related injury to participants will be handled, consistent with the informed consent form. A mismatch between the consent form and the indemnity clause is a frequent negotiation point.
Intellectual property and publication
Industry sponsors expect to own inventions arising from the protocol and the investigational product, while institutions seek to keep background IP and rights to use results for non-commercial research and teaching. Publication clauses usually give the sponsor a review period to remove confidential information and file patent applications, with a short delay right but no veto. For multi-site studies, the clause should respect the agreed primary publication. Our life sciences licensing team handles IP terms when the results feed into a licence.
Budget, payments and charging participants
Budgets should separate per-patient fees, start-up costs, pass-through costs and screen-failure payments, with clear invoicing triggers. MOH has issued guidance on charging research subjects, so any arrangement where participants or their insurers pay for study procedures needs specific review. Payments to investigators should be made to the institution under its policies, not privately.
Data protection and confidentiality
Trial data are personal data in the hands of the site, and often remain identifiable to the sponsor through codes. The Personal Data Protection Act 2012 and the PDPC's advisory guidelines for the healthcare sector apply alongside the HBRA's confidentiality duties. Contracts should cover coding, cross-border transfer safeguards, breach notification and retention. See also our health data governance practice.
Termination, recruitment and early close-out
Sponsors want the right to stop a study at any time for safety, futility or business reasons; institutions want payment for work done, costs they cannot cancel and an orderly transition for enrolled participants. A balanced clause pays for completed visits and non-cancellable commitments, requires continued care or follow-up where the protocol or ethics approval demands it, and preserves records, CRM accountability and safety reporting after termination. Recruitment targets should be estimates, not warranties, unless the budget reflects the risk.
Investigator-initiated studies
A growing share of clinical trials in Singapore are investigator-initiated, with the institution as sponsor and a company providing drug supply or funding. Here the roles reverse: the institution carries the regulatory responsibility, owns the protocol and usually the results, and the company receives a report, a right to review publications and sometimes an option over inventions involving its product. The company must avoid steering the study in a way that makes it the de facto sponsor, and its support agreement should cover drug supply quality, safety data exchange and limits on promotional use of results.
A clinical trial agreement that does not mirror the regulatory allocation of duties is not a risk-sharing tool; it is a source of disputes.
Process and timeline from feasibility to close-out
The sequence below reflects an industry-sponsored drug study requiring a CTA at a public institution. Investigator-initiated and device studies follow a similar contractual path with different regulatory steps.
- Feasibility and confidentiality. Sign a confidentiality agreement with the site, share the synopsis and agree the local sponsor arrangement.
- Classify the study. Confirm whether a CTA, CTN or CTC is needed, or whether the study sits only under the HBRA, using HSA's guidance on route determination.
- Prepare submissions. Assemble the protocol, English informed consent form, investigator's brochure, principal investigator CV, GMP certificates and certificates of analysis; submit through PRISM and to the IRB.
- Negotiate the agreements. Run clinical trial agreement and budget negotiation in parallel with regulatory review, using the institution's template where possible.
- Handle clinical research materials. Make any required CRM notification before import, and arrange labelling, storage and accountability.
- Activate and conduct. Hold site initiation, then manage amendments, safety reporting and monitoring under ICH E6 (R3).
- Close out and archive. Reconcile and dispose of or export unused CRM within six months, and archive essential records for the required period.
Safety reporting, GCP and records
The local sponsor must report unexpected serious adverse drug reactions to HSA no later than 7 calendar days after awareness for fatal or life-threatening cases, with a follow-up within 8 further days, and no later than 15 calendar days for other cases. Under the HBRA, research institutions report serious adverse events to MOH on parallel 7-day and 15-day timelines. Agreements must make sure information reaches the person who reports in time.
HSA implemented the principles and Annex 1 of ICH E6 (R3) on 1 January 2026, with Annex 2 on decentralised and real-world elements following on 1 January 2027. HSA runs routine, triggered and pre-approval GCP inspections of sites, sponsors and CROs, grading findings as critical, major or other.
Essential records must be kept until the latest of six years after the trial ends, two years after the last product registration is granted, two years after HSA is told of termination, or longer periods for CTGTP traceability. Contracts and archiving budgets should reflect these periods, which may outlast the commercial relationship.
Risks and common mistakes
Using a global template that ignores the local sponsor
Global clinical trial agreement templates often assume that the sponsor is the overseas parent and the CRO is a service provider. In Singapore, HSA looks to the local sponsor, a locally registered entity, for the trial. If the CRO is acting as local sponsor, the agreement chain must say so and pass through the obligations and protections that role carries, including safety reporting and regulatory correspondence. Otherwise the CRO carries regulatory responsibility without the contractual authority or indemnity to discharge it, and the parent faces gaps in its control of the trial.
Misclassifying the study
A registered drug used off-label needs a CTA, not a CTN. A device study needs no HSA trial approval but is fully subject to HBRA governance. An observational study that drifts into protocol-driven treatment assignment stops being observational. Getting classification wrong can mean conducting a trial without the right authorisation. Record the classification reasoning, use HSA's route-determination guidance and reassess when the protocol is amended.
Indemnity that does not match the consent form
Participants are told in the informed consent form how trial-related injury will be handled. If the sponsor's indemnity and insurance are narrower than that promise, the institution is exposed and the participant may be misled. Ethics committees and institutions increasingly check alignment. Draft the injury language once, approved by both legal and clinical teams, and use it consistently in the consent form, the agreement and the insurance certificate.
Unplanned future use of samples and data
Sponsors often want to keep samples and data for future research. Under the HBRA, that requires appropriate consent covering the future use and compliance with the tissue framework, and the prohibition on commercial trading of human tissue must be respected. Data sent overseas must meet PDPA transfer requirements. Decide at protocol stage what future use is intended, reflect it in the consent form and the material transfer agreement, and set retention and destruction rules.
Leaving clinical research materials loose at close-out
For locally manufactured or imported CRM, the local sponsor must make sure unused material is disposed of or exported within six months of the study ending, and needs HSA's written permission before any other use. Close-out plans often focus on data and forget the drug. Assign CRM reconciliation in the site agreement and the depot contract, and budget for destruction or export.
Cross-border angle
Most industry clinical trials in Singapore are part of multinational programmes, so Singapore agreements sit inside global master agreements governed by foreign law. That is workable, but site agreements with Singapore institutions are commonly governed by Singapore law, and the institution's policies will prevail on matters such as payments and publication. Align dispute resolution clauses across the chain; Singapore-seated arbitration is a common neutral choice.
For sponsors from Bangladesh, China or the UAE using Singapore as a regional hub, the local sponsor requirement and English-language documentation are the first practical hurdles. Samples shipped to laboratories in the UK, EU or China need export arrangements and data transfer safeguards. HSA's Innovation Office offers free early scientific and regulatory advice on novel products, responding within 20 working days on whether it will meet or reply in writing.
Negotiate the clinical trial agreement in parallel with HSA and IRB review, not after. Agreement delays, not regulatory review, are the most common reason a site misses its activation date.
How TRW & Co helps with clinical trials in Singapore
We advise sponsors, CROs, biotech companies and research institutions on the contracts and regulatory allocation behind clinical trials in Singapore. We coordinate with clinical operations and regulatory teams, and where Singapore court or tribunal representation is required, we work alongside Singapore-qualified counsel.
Study structuring
We confirm the regulatory route, identify the local sponsor and map duties across sponsor, CRO, site and depot before contracts are drafted.
Agreement drafting and negotiation
We prepare and negotiate clinical trial agreements, CRO agreements, material transfer and data sharing agreements, aligned with institutional templates.
Data and tissue compliance
We review consent forms, PDPA transfer mechanisms and HBRA tissue requirements, so that future research use is lawful and documented.
Issues and disputes
We support GCP inspection responses, budget and IP disputes and early terminations, working with our healthcare regulation colleagues.
See our practices for the wider offering, or contact us about a study. Our article on research IP collaboration covers ownership models in more depth.
Checklist for decision-makers
- Have we classified the study as CTA, CTN, CTC or HBRA-only, and recorded the reasoning?
- Which locally registered entity is the local sponsor, and do the contracts reflect that role?
- Are submissions to HSA and the IRB sequenced correctly, with agreement negotiation running in parallel?
- Do indemnity, insurance and the consent form say the same thing about trial-related injury?
- Are IP, publication and data-use terms acceptable to both sponsor and institution?
- Can the safety reporting chain meet the 7-day and 15-day deadlines?
- Do we have consent and contracts for any future use of samples and data?
- Are CRM disposal and record retention periods budgeted beyond the end of the study?
Answering these questions early is the most reliable way to keep clinical trials in Singapore on schedule and free of avoidable disputes.
Frequently asked questions
01Do all clinical trials in Singapore need HSA approval?
No. Trials of therapeutic products and Class 2 cell, tissue and gene therapy products need a Clinical Trial Authorisation or Notification from HSA, and trials of medicinal products need a Clinical Trial Certificate. Medical device trials, Class 1 CTGTP studies and observational studies do not need HSA trial approval, but they are governed by the Human Biomedical Research Act, which requires supervision by a research institution and review by an institutional review board. Device CRM is still subject to HSA controls, so classification should be recorded at the outset.
02Can a foreign company be the sponsor of a trial in Singapore?
It can sponsor the global programme, but for HSA purposes a local sponsor is needed: a locally registered entity that takes responsibility for initiating, managing or financing the trial in Singapore. Foreign companies usually use a Singapore affiliate or a CRO as local sponsor. The sponsor can delegate tasks to the CRO but remains responsible for them. The agreements should allocate safety reporting, regulatory correspondence, records and costs, and give the local sponsor enough information and authority to meet HSA requirements.
03How long does it take to start a trial at a Singapore hospital?
Regulatory targets are short: 30 working days for a standard CTA and 5 for a CTN, with no HSA fees. The practical timeline also depends on IRB review, the clinical trial agreement and budget negotiation, CRM import and site initiation. A CTA can be submitted in parallel with the IRB, but a CTN only after IRB approval. Running contract negotiation alongside regulatory review, and using the institution's template, is the most effective way to shorten the overall time to first patient.
04Who owns the results of an industry-sponsored trial?
It depends on the agreement. Industry sponsors normally own inventions and data arising from the protocol and their product, while institutions keep their background IP and often a licence to use results for non-commercial research and teaching. Investigators generally retain the right to publish after a sponsor review period that allows removal of confidential information and patent filing. Investigator-initiated studies often reverse these defaults, with the institution owning results and the company receiving rights in data about its product.
05What safety reports must the sponsor make to HSA?
The local sponsor must report unexpected serious adverse drug reactions: fatal or life-threatening cases no later than 7 calendar days after awareness, with a follow-up within 8 further days, and other cases no later than 15 calendar days. Follow-up information is reported as it becomes available. For HBRA studies, research institutions report serious adverse events to MOH on similar 7-day and 15-day timelines. Agreements with sites, CROs and overseas safety teams should ensure that information reaches the reporting party in time.
06How long must trial records be kept?
HSA requires essential records to be retained until the latest of six years after the trial ends, two years after the last product registration is granted (once no further application is contemplated), two years after HSA is told of an early termination, or 30 years after expiry for CTGTP traceability records, or any other period HSA directs. The sponsor and principal investigator each retain their own records. Archiving obligations and costs should be written into the clinical trial agreement because they outlast the study.
Sources and official materials
- HSA: Overview of clinical trials regulation — Which regulations apply to each product type; CRM rules
- HSA: Apply for CTA or CTN — Criteria, documents and turnaround targets
- Health Products (Clinical Trials) Regulations 2016 — Trial authorisation and conduct for therapeutic products
- Human Biomedical Research Act 2015 — Research institutions, IRBs, consent and tissue
- MOH: Regulation of human biomedical research — HBRA guidance, notifications and circulars
- HSA: Adverse event reporting in clinical trials — 7-day and 15-day reporting by the local sponsor
- HSA: Good Clinical Practice inspections — Inspection types and ICH E6 (R3) implementation
General information only, current as at 20 October 2026. It is not legal advice and does not create a lawyer–client relationship. Singapore law and regulatory practice change; check current official sources and take advice on the facts of your matter.
Talk it through
before you decide.
Share the decision, the jurisdictions and the timetable. A partner will tell you what matters, what can wait and what it will take.